ProfileGDS5678 / 1456582_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 77% 76% 74% 75% 78% 75% 75% 75% 75% 76% 75% 76% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0981776
GSM967853U87-EV human glioblastoma xenograft - Control 25.2231377
GSM967854U87-EV human glioblastoma xenograft - Control 35.0691176
GSM967855U87-EV human glioblastoma xenograft - Control 45.0032374
GSM967856U87-EV human glioblastoma xenograft - Control 55.0052275
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1602978
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8877375
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9088575
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.9509975
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.0502375
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.0482176
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.0318975
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.0562776
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.0557876